Yinxieling attenuates psoriasis in mice by regulating oxidative stress and lipid mediators to correct immune cell disorder through the NF-κB/Nrf2 signaling pathways

This is the authors' abstract. We don't add key points for this paper.

Psoriasis is a chronic skin disease that causes inflammation over time due to immune cell-mediated inflammation, oxidative stress, and lipid mediator imbalance. This study was to investigate the impact of Yinxieling (YXL), a reliable Chinese medicine for the treatment of psoriasis vulgaris, on the redox balance and lipid mediators in mice with IMQ-induced psoriasis. Daily application of aqueous extract of YXL on IMQ-induced psoriasis-like mice, the efficacy and mechanism of YXL were evaluated by appearance symptoms, oxidative stress indicators, immune balance, and lipid metabolism indicators. The results demonstrated that YXL significantly enhanced therapeutic efficacy in a psoriasis mouse model, markedly improving the PASl scores and cutaneous inflammation. Upon YXL treatment, lipid peroxidation levels were significantly reduced, while antioxidant levels correspondingly increased. Additionally, YXL modulated the metabolic enzymes associated with 2-AG, which led to a decrease in CB1 receptor expression and an increase in CB2 receptor expression. In terms of immune modulation, YXL treatment promoted the regulation of T cell populations by down-regulating Th1, Th17, and γδT cells, while up-regulating Th2 and Treg cells, thereby facilitating the formation of an anti-inflammatory state. Further analysis indicated that these regulatory effects were closely associated with the down-regulation of NF-kB expression and the up-regulation of Nrf2 expression. In conclusion, YXL reduces mice dermatitis by inhibiting oxidative stress, elevating endocannabinoid levels and balancing T cell populations in IMQ-induced psoriasis through the NF-κB and Nrf2 signaling pathways. Our results suggest its potential as a therapeutic option for psoriasis by targeting multiple pathways involved in the disease's development.